REFERENCES
- Serjeant GR. Sickle cell disease. Lancet. 1997;350:725–730.
- Stuart MJ, Nagel RL. Sickle-cell disease. Lancet. 2004;364:1343–1360.
- Roseff SD. Sickle cell disease: a review. Immunohematology. 2009;25:67–74.
- Voskaridou E, Christoulas D, Bilalis A, The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle-cell syndromes: results of a 17-year, single center trial (LaSHS). Blood. 2010;115:2354–2363.
- Strouse JJ, Lanzkron S, Beach MC, Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. Pediatrics. 2008;122:1332–1342.
- Thornburg CD, Dixon N, Burgett S, A pilot study of hydroxyurea to prevent chronic organ damage in young children with sickle cell anemia. Pediatr Blood Cancer. 2009;52:609–615.
- Segal JB, Strouse JJ, Beach MC, Hydroxyurea for the treatment of sickle cell disease. Evid Rep Technol Assess (Full Rep). 2008;(165):1–95.
- Moheeb H, Wali YA, El-Sayed MS. Physical fitness indices and anthropometrics profiles in schoolchildren with sickle cell trait/disease. Am J Hematol. 2007;82:91–97.
- Peterson MJ, Czerwinski SA, Siervogel RM. Development and validation of skinfold-thickness prediction equations with a 4-compartment model. Am J Clin Nutr. 2003;77:1186–1191.
- Durnin JVGA, Wormersley J. Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged 16 to 72 years. Br J Nutr. 1974;32:77–97.
- Cepeda ML, Allen FH, Cepeda NJ, Yang YM. Physical growth, sexual maturation, body image and sickle cell disease. J Natl Med Assoc. 2000;92:10–14.
- Soliman AT, el Banna NM, alSalmi IA, Growth hormone secretion and circulating insulin-like growth factor-I (IGF-I) and IGF binding protein-3 concentrations in children with sickle cell disease. Metabolism. 1997;46:1241–1245.
- Buchowski MS, Chen KY, Byrne DA, Wang WC. Equation to estimate resting energy expenditure in adolescents with sickle cell anemia. Am J Clin Nutr. 2002;76:1335–1344.
- Buchowski MS, Townsend KM, Chen KY. Patterns of energy expenditure in adolescents with sickle cell anemia. J Pediatrics. 2002;140:86–92.
- Williams RA, Mackert PP, Fletcher LA, Comparison of energy prediction equations with measured resting energy expenditure in children with sickle cell disease. J Am Diet Assoc. 2002;102:956–961.
- Holocomb WR. Stretching and warm-up. In: Baechle TR, Earle RW, eds. Essentials of Strength Training and Conditioning. Champaign IL: Human Kinetics; 2000:321–329.
- Vichinsky EP. Hydroxyurea in children: present and future. Semin Hematol. 1997;34(3 Suppl 3):22–29.
- Charache S. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Semin Hematol. 1997;34(3 Suppl 3):15–21.
- Ballas SK, Dover GJ, Charache S. Effect of hydroxyurea on the rheological properties of sickle erythrocytes in vivo. Am J Hematol. 1989;32:104–111.
- Fathallah H, Atweh GF. Induction of fetal hemoglobin in the treatment of sickle cell disease. Hematology Am Soc Hematol Educ Program. 2006:58–62.
- Lou TF, Singh M, Mackie A, Hydroxyurea generates nitric oxide in human erythroid cells: mechanisms for gamma-globin gene activation. Exp Biol Med (Maywood). 2009;234:1374–1382.
- Heeney MM, Ware RE. Hydroxyurea for children with sickle cell disease. Hematol Oncol Clin North Am. 2010;24:199–214.
- Ballas SK, Marcolina MJ, Dover GJ, Barton FB. Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. Br J Haematol. 1999;105:491–496.
- Odièvre MH, Bony V, Benkerrou M, Modulation of erythroid adhesion receptor expression by hydroxyurea in children with sickle cell disease. Haematologica. 2008;93:502–510.
- Cartron JP, Elion J. Erythroid adhesion molecules in sickle cell disease: effect of hydroxyurea. Transfus Clin Biol. 2008;15:39–50.
- Anderson N. Hydroxyurea therapy: improving the lives of patients with sickle cell disease. Pediatr Nurs. 2006;32:541–543.
- Potteiger JA. Aerobic endurance exercise prescription. In: Baechle TR, Earle RW, eds. Essentials of strength Training and Conditioning. Champaign IL: Human Kinetics; 2000:495–508.
- Ware RE, Aygun B. Advances in the use of hydroxyurea. Hematology Am Soc Hematol Educ Program. 2009:62–69.
- Lee MT, Rosenzweig EB, Cairo MS. Pulmonary hypertension in sickle cell disease. Clin Adv Hematol Oncol. 2007;5:645–653, 585.
- Olnes M, Chi A, Haney C, Improvement in hemolysis and pulmonary arterial systolic pressure in adult patients with sickle cell disease during treatment with hydroxyurea. Am J Hematol. 2009;84:530–532.